

PHARMACY GNIPST BULLETIN

Volume-4, Issue- 1




**GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY**
157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India

Table of Contents

- 01 Message from Director and Principal**
- 02 Recent Researches**
- 03 New Drug Approvals**
- 04 Clinical Trial News**
- 05 Disease Outbreak News**
- 06 Campus News**
- 07 Special Page and Game time**



MESSAGE FROM HONORABLE DIRECTOR



As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings and best wishes to all our students, faculty members, staff, alumni, and well-wishers on the auspicious occasion of Swami Vivekananda's Birthday, celebrated as National Youth Day.

Swami Vivekananda was a beacon of knowledge, strength, self-belief, and service to humanity. His timeless teachings inspire us to awaken our inner potential, cultivate character, and dedicate ourselves to the

upliftment of society. He firmly believed that education is the manifestation of perfection already present in human beings—a philosophy that continues to guide our academic and moral vision.

At GNIPST, we strive to empower young minds with not only scientific knowledge and professional competence but also values such as discipline, integrity, empathy, and social responsibility. The ideals of Swami Vivekananda resonate deeply with our commitment to holistic education and nation-building through youth empowerment.

On this significant day, let us encourage our students to think fearlessly, act ethically, and work tirelessly for the betterment of society. As educators and mentors, may we continue to guide them toward excellence, innovation, and service.

Let us commemorate this occasion by renewing our dedication to shaping confident professionals and responsible citizens who can lead with wisdom and compassion.

Warm wishes to all on National Youth Day.

Prof. (Dr.) Abhijit Sengupta



MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and heartfelt best wishes to our students, faculty members, staff, alumni, and valued partners on the auspicious occasion of Swami Vivekananda's Birthday, observed as National Youth Day on 12th January.



Swami Vivekananda was a visionary philosopher and a guiding light for youth empowerment, whose teachings on self-belief, discipline, character building, and service to humanity continue to inspire generations. His profound message—“Arise, awake, and stop not till the goal is reached”—reminds us of the transformative power of education and the limitless potential of young minds.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we believe that education is the most meaningful instrument for national development—one that enlightens intellect, strengthens character, and nurtures responsible citizenship. Since our inception in 2005, GNIPST has grown into a distinguished centre of pharmaceutical education, recognized by the Pharmacy Council of India (PCI), accredited by NAAC and NBA, and ranked 85th in NIRF 2025, reflecting our unwavering commitment to academic excellence and continuous progress.

On this significant day, let us reaffirm our collective responsibility to guide and inspire our students by fostering an environment that promotes academic excellence, ethical values, innovation, and holistic development. May the ideals of Swami Vivekananda motivate our youth to lead with courage, integrity, and compassion in service of society and the nation.

Warm wishes to all on Swami Vivekananda Jayanti and National Youth Day.

Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



WHO launches new, unified plan for countries to manage coronaviruses: COVID-19 and beyond

MORE INFO

www.who.int/

Global experts convene in Vienna to discuss radiation protection in medicine

MORE INFO

www.who.int/

Medical Product Alert N°6/2025: Falsified SIMULECT (basiliximab) for injection

MORE INFO

www.who.int/

WHO launches a call for high-level experts to join the Science Council

MORE INFO

www.who.int/

The World Health Organization (WHO) has released a new strategic plan for the management of coronavirus disease threats, including COVID-19, Middle East respiratory syndrome (MERS), and potential new coronavirus diseases. This is the first such unified plan for coronavirus disease threats, marking a turning point in the transition from the COVID-19 emergency response to sustained, long-term, and integrated management. Building on the lessons of the past five years of COVID-19 response and ongoing work on MERS and other respiratory diseases, the Strategic plan for coronavirus disease threat management: advancing integration, sustainability, and equity, 2025–2030 guides national health authorities and partners in taking a coherent, action-oriented approach to managing coronavirus disease threats in the broader context of infectious disease management.

Global health leaders convene at the IAEA headquarters in Vienna this week to advance radiation safety in medicine. The International Conference on Radiation Protection in Medicine: X Ray Vision, organized by the IAEA and co-sponsored by the World Health Organization (WHO) and the Pan American Health Organization (PAHO), brings together experts to review global developments in radiation protection and safety of patients and health professionals, as well as discussing future challenges and opportunities.

This WHO Medical Product Alert refers to falsified SIMULECT (basiliximab) for injection. The falsified product has been detected in Rwanda, Bulgaria, and Türkiye, and was reported to the WHO in December 2024 and November 2025. SIMULECT (basiliximab) is an immunosuppressant medicine classified as a monoclonal antibody. It is indicated for the prevention of acute organ rejection in adults and children undergoing kidney transplantation. SIMULECT is supplied as a powder vial with or without a water for injection (solvent) ampoule for reconstitution, and is administered either as an intravenous infusion or as an injection, usually in a hospital setting.

The World Health Organization (WHO) is today soliciting the interest of internationally-renowned experts to serve on its Science Council, one of the Organization's highest-level advisory bodies to the WHO Director-General. In a rapidly evolving scientific landscape, WHO is committed to reinforcing its global leadership in health sciences and innovation. Through the Chief Scientist's Office, the Science Division guides the Organization's scientific direction, supports the development of health norms and standards, promotes ethical and equitable research ecosystems, and ensures that evidence is translated into impactful policy and action.

FDA



NEW DRUG APPROVALS

December, 2025

Avance (acellular nerve allograft-arwx) for Surgical Implantation

- Date of Approval: December 3, 2025
- Company: Axogen, Inc.
- Treatment for: Nerve Discontinuities



Nuzolvence (zolifludacin) Granules for Oral Suspension

- Date of Approval: December 12, 2025
- Company: Innoviva Specialty Therapeutics, Inc.
- Treatment for: Gonococcal Infection, Uncomplicated



Fesilty (fibrinogen, human-chmt) Lyophilized Powder for Injection

- Date of Approval: December 16, 2025
- Company: Grifols
- Treatment for: Congenital Fibrinogen Deficiency



Waskyra (etuvetidigene autotemcel) Suspension for Intravenous Infusion

- Date of Approval: December 9, 2025
- Company: Fondazione Telethon
- Treatment for: Wiskott-Aldrich Syndrome



Nereus (tradipitant) Capsules

- Date of Approval: December 30, 2025
- Company: Vanda Pharmaceuticals Inc.
- Treatment for: Motion Sickness



Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Injection

- Date of Approval: December 17, 2025
- Company: Johnson & Johnson
- Treatment for: Non Small Cell Lung Cancer



VBoncresa (denosumab-mobz) Injection

- Date of Approval: December 19, 2025
- Company: Amneal Pharmaceuticals, Inc.
- Treatment for: Osteoporosis

<https://www.drugs.com/newdrugs-archive/2025.html>



CLINICAL TRIAL NEWS



01.

Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company") today announced topline results from the global Phase 3 "DRAGON" trial of Tinlarebant, marking the first successful pivotal trial in patients with Stargardt disease type 1 (STGD1). STGD1 is an eye disease that leads to progressive vision loss, usually beginning in childhood or young adulthood, and currently has no approved treatment worldwide.

02.

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced RAPIDe-3 pivotal data confirming the potential of deucrictibant's differentiated profile for the on-demand treatment of HAE attacks.

03.

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

WALTHAM, Mass. and BOULDER, Colo., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ: COGT) today announced positive top-line results from the registration-directed APEX Part 2 clinical trial of bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) demonstrating clinically meaningful results as measured by consensus criteria used to assess patient response.

04.

GSK'227, a B7-H3-Targeted Antibody-Drug Conjugate, Granted Orphan Drug Designation in Small-Cell Lung Cancer by the US FDA

London, UK December 10, 2025 -- GSK plc (LSE/NYSE: GSK) today announced that its B7-H3-targeted antibody-drug conjugate GSK'227, now referred to by its International Nonproprietary Name, risvutatug rezetecan, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of small-cell lung cancer (SCLC).

05.

Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

OSAKA Japan AND CAMBRIDGE, Massachusetts, December 18, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).

06.

Update on LATIFY Phase III Trial of Ceralasertib plus Imfinzi in Previously Treated Advanced Non-Small Cell Lung Cancer

22 December 2025 -- The LATIFY Phase III trial of ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) versus standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The trial evaluated patients without actionable genomic alterations (AGAs) whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.

07.

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for ulixacaltamide, a differentiated and highly selective small molecule inhibitor of T-type calcium channels, for the treatment of patients with essential tremor (ET).

MORE INFORMATION

https://www.drugs.com/clinical_trials/praxis-precision-medicines-announces-fda-has-granted-breakthrough-therapy-designation-22271.html



DISEASE OUTBREAK NEWS (DONS)

December 2025

Seasonal influenza - Global situation

Situation at a glance

Seasonal influenza ('the flu') is an acute respiratory infection caused by influenza viruses that circulate globally and year-round. It can cause illness ranging from mild to severe, sometimes resulting in hospitalization or death. Seasonal influenza activity has increased globally in recent months, with an increased proportion of seasonal influenza A(H3N2) viruses being detected. This rise coincides with the onset of winter in the northern hemisphere and an increase in acute respiratory infections caused by influenza and other respiratory viruses typically observed at this time of year. Although global activity remains within expected seasonal ranges, early increases and higher activity than typical at this time of year have been observed in some regions. Seasonal influenza viruses, including A(H3N2) viruses, continually evolve over time. Since August 2025, there has been a rapid increase of A(H3N2) J.2.4.1 alias K subclade viruses detected from several countries based on available genetic sequence data. These subclade K viruses have several changes from related A(H3N2) viruses.

MORE INFO <https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573>

10 December 2025




Middle East respiratory syndrome coronavirus - Global update

24 December 2025

Situation at a glance

Since the beginning of 2025 and as of 21 December 2025, a total of 19 cases of Middle East respiratory syndrome coronavirus (MERS-CoV), including four deaths have been reported to WHO globally. Of the 19 cases, 17 were reported by the Kingdom of Saudi Arabia (KSA), and two were reported from France. Between 4 June and 21 December 2025, the Ministry of Health (MoH) of KSA reported a total of seven cases of MERS-CoV infection, including two deaths. In addition, at the beginning of December 2025, the National IHR Focal Point (IHR NFP) for France also reported two MERS-CoV travel-associated cases; involving individuals with recent travel to countries in the Arabian Peninsula. The notification of these latest cases does not change the overall risk assessment, which remains moderate at both the global and regional levels. These cases show that the virus continues to pose a threat in countries where it is circulating in dromedary camels, with regular spillover into the human population. WHO recommends implementation of targeted infection, prevention and control (IPC) measures to prevent the spread of health care-associated infections of MERS-CoV and onward human transmission.



MORE INFO <https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>

CAMPUS NEWS



1. World Meditation Day 2025: The Nabachetana Yoga and Meditation Club of GNIPST joyfully celebrated World Meditation Day 2025, fostering a spirit of inner peace, mindfulness, and holistic well-being among students and faculty. The event highlighted the importance of meditation in maintaining mental clarity, emotional balance, and overall wellness in today's fast-paced life. The active participation and positive energy made the celebration truly meaningful and inspiring.



1. JIS SPIRIT 2026: Our GNIPST participants delivered outstanding performances through group dance, recitation, sports and anchoring, making us truly proud of JIS Spirit 2026, organized by the JIS Group.



MORE DETAILS

NATIONAL YOUTH DAY

12 January 2026


National Youth Day, also known as Swami Vivekananda Jayanti, is celebrated on 12 January every year to mark the birth anniversary of Swami Vivekananda. In 1984, the Government of India officially declared his birthday as National Youth Day, recognizing his timeless vision for empowering youth. Swami Vivekananda regarded young people as the driving force of national regeneration and emphasized strength of character, self-confidence, and service to humanity. National Youth Day 2026 continues to inspire the youth of India to channel their energy, intellect, and moral values toward nation-building and social transformation.

Significance


- It highlights the importance of youth in shaping the future of the nation.
- It promotes the ideals of confidence, courage, and self-discipline.
- It inspires social responsibility and service-oriented thinking.
- It encourages unity, harmony, and national integration.
- It reinforces ethical leadership and constructive contribution by youth.



GNIPST GAME TIME



Cross Word



ACROSS

4. Fraction of administered dose reaching systemic circulation
5. Biphasic liquid dosage form with insoluble solids
8. Commonly used analgesic and antipyretic
9. Drug used to relieve pain
10. First line oral antidiabetic drug

DOWN

1. Relating to liver metabolism of drugs
2. Study of drugs and their effects on the body
3. Excipient that helps tablet break apart after administration
6. Process of combining API with excipients into dosage form
7. Drug used to treat bacterial infections

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



SCAN
ME

CLICK
HERE

Celebrating the Achievers!



Shaswati Ghosh
B. Pharm, 6th Semester

26-27
February
2026

International Conference on **FRONTIERS IN MEDICAL, PHARMACEUTICAL AND ALLIED SCIENCES:**

Translating Innovation into impact.

Thank you

for the **Overwhelming Response to the Early Bird
Registration and Abstract Submission!**

Registrations Remain Open!

Category	Registration Amount
Delegates (Student)	Rs. 2500
Other Delegates (Faculty/ Industry)	Rs. 3000
Foreign Delegates (Student)	USD 150
Other Foreign Delegates	USD 200

FOR REGISTERING:



<https://forms.gle/TEUh43LPZnS2Smab9>

PAYMENT DETAILS



- Account No.: 33958108105
- IFSC Code: SBIN0016642
- Branch Name: GNCC
- Account Type: Current

MORE INFO

📞 Dr. Sumana Roy (9932867684),
📞 Ms. Prapti Chakraborty (8902364980)
✉️ gnipstconference@gmail.com

Editorial Board

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamudra Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters

Cipla
RnD SOLUTIONS

ZIFO
Cognizant

Nestlé

wipro
TRIMPLIN

IQVIA

MACLEODS

FRESENIUS
KABI

tcs

**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com